… Michael J. Fox Foundation and covered subjects including common but lesser known non-motor symptoms, current treatments and the potential causes of … and movement disorder specialist  Rachel Dolhun , MD, vice president of medical communication. More typical, she says, …

… (PD), for accurate and earlier diagnosis, and for monitoring treatment effects. We are investigating two potential … the tests accurately diagnose PD, whether they reflect predicted effects of CoQ10 on metabolism and gene … their assigned study drug (CoQ10 or placebo), and will compare their blood samples with those from people without …

… this week that it has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) seeking approval for its drug Nuplazid (the compound pimavanserin) for the treatment of psychosis … sleep disturbance, cognitive impairment, dementia and depression. Right now doctors may prescribe anti-schizophrenic …

… Cancel Register for Webinar How Genetic Discoveries Lead to Parkinson's Therapies First Name   Last Name   Email   … had PD I am a researcher, clinician or work with the PD community Other   Diagnosis Date ${selected} Jan Feb Mar Apr … on July 18, 2019. This month, we replay a popular webinar where our panelists discuss ongoing trials targeting genetic …

… This grant builds upon the research from a prior grant: Comparitive gene expression analysis of the brain in Parkinson's Disease and in … that the available anxiety questionnaires are not suitable to assess anxiety in Parkinson’s disease (PD). The different …

… at The Michael J. Fox Foundation offices in New York City to discuss a leading strategy to stop Parkinson's disease: targeting GBA . Mutations in the GBA gene are present in five to 10 percent of people with Parkinson's disease (PD), representing one of the most common genetic risk factors for this disorder. The GBA gene …